Terms: = Breast cancer AND NSD1, FLJ44628, 64324, ENSG00000165671, Q96L73, FLJ22263, DKFZp666C163, ARA267, STO, SOTOS AND Treatment
15 results:
1. treatment side affects exercising microvascular oxygenation response in active breast cancer survivors: A pilot study.
Cayot TE; Herbert B; Klika RJ
Clin Physiol Funct Imaging; 2023 Mar; 43(2):96-102. PubMed ID: 36376074
[TBL] [Abstract] [Full Text] [Related]
2. Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With breast cancer in a Controlled Randomized Clinical Trial.
Johansson A; Dar H; van 't Veer LJ; Tobin NP; Perez-Tenorio G; Nordenskjöld A; Johansson U; Hartman J; Skoog L; Yau C; Benz CC; Esserman LJ; Stål O; Nordenskjöld B; Fornander T; Lindström LS
J Clin Oncol; 2022 Dec; 40(35):4071-4082. PubMed ID: 35862873
[TBL] [Abstract] [Full Text] [Related]
3. Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature.
Opdam M; van der Noort V; Kleijn M; Glas A; Mandjes I; Kleiterp S; Hilbers FS; Kruger DT; Bins AD; de Jong PC; Schiphorst PPJBM; van Dalen T; Flameling B; Rietbroek RC; Beeker A; van den Heiligenberg SM; Bakker SD; Wymenga ANM; Oving IM; Bijlsma RM; van Diest PJ; Vermorken JB; van Tinteren H; Linn SC
Breast Cancer Res Treat; 2022 Jul; 194(2):265-278. PubMed ID: 35587322
[TBL] [Abstract] [Full Text] [Related]
4. Knockdown of nuclear receptor binding SET domain-containing protein 1 (nsd1) inhibits proliferation and facilitates apoptosis in paclitaxel-resistant breast cancer cells via inactivating the Wnt/β-catenin signaling pathway.
Chen Y; Li X; Xu J; Xiao H; Tang C; Liang W; Zhu X; Fang Y; Wang H; Shi J
Bioengineered; 2022 Feb; 13(2):3526-3536. PubMed ID: 35200072
[TBL] [Abstract] [Full Text] [Related]
5. Nuclear receptor binding SET domain protein 1 promotes epithelial-mesenchymal transition in paclitaxel-resistant breast cancer cells via regulating nuclear factor kappa B and F-box and leucine-rich repeat protein 11.
Chen Y; Tang W; Zhu X; Zhang L; Zhu Y; Xiao H; Xu J; Fang Y; Li X; Tang C; Shi J
Bioengineered; 2021 Dec; 12(2):11506-11519. PubMed ID: 34905470
[TBL] [Abstract] [Full Text] [Related]
6. Early detection onset of flap failure using near infrared spectroscopy.
Sircan-Kucuksayan A; Ozkan O; Ozkan O; Kucuksayan E; Unal K; Canpolat M
J Plast Surg Hand Surg; 2022 Jun; 56(3):145-150. PubMed ID: 34323644
[TBL] [Abstract] [Full Text] [Related]
7. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative breast cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the stockholm Tamoxifen Randomized Clinical Trial.
Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
[TBL] [Abstract] [Full Text] [Related]
8. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO sto 0217).
Tintelnot J; Goekkurt E; Binder M; Thuss-Patience P; Lorenzen S; Knorrenschild JR; Kretzschmar A; Ettrich T; Lindig U; Jacobasch L; Pink D; Al-Batran SE; Hinke A; Hegewisch-Becker S; Nilsson S; Bokemeyer C; Stein A
BMC Cancer; 2020 Jun; 20(1):503. PubMed ID: 32487035
[TBL] [Abstract] [Full Text] [Related]
9. Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.
van 't Veer LJ; Yau C; Yu NY; Benz CC; Nordenskjöld B; Fornander T; Stål O; Esserman LJ; Lindström LS
Breast Cancer Res Treat; 2017 Nov; 166(2):593-601. PubMed ID: 28776283
[TBL] [Abstract] [Full Text] [Related]
10. Use of Molecular Tools to Identify Patients With Indolent breast cancers With Ultralow Risk Over 2 Decades.
Esserman LJ; Yau C; Thompson CK; van 't Veer LJ; Borowsky AD; Hoadley KA; Tobin NP; Nordenskjöld B; Fornander T; Stål O; Benz CC; Lindström LS
JAMA Oncol; 2017 Nov; 3(11):1503-1510. PubMed ID: 28662222
[TBL] [Abstract] [Full Text] [Related]
11. Predicting Responses to Neoadjuvant Chemotherapy in breast cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging.
Tromberg BJ; Zhang Z; Leproux A; O'Sullivan TD; Cerussi AE; Carpenter PM; Mehta RS; Roblyer D; Yang W; Paulsen KD; Pogue BW; Jiang S; Kaufman PA; Yodh AG; Chung SH; Schnall M; Snyder BS; Hylton N; Boas DA; Carp SA; Isakoff SJ; Mankoff D;
Cancer Res; 2016 Oct; 76(20):5933-5944. PubMed ID: 27527559
[TBL] [Abstract] [Full Text] [Related]
12. Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy.
Katoh M
Epigenomics; 2016 Feb; 8(2):285-305. PubMed ID: 26411517
[TBL] [Abstract] [Full Text] [Related]
13. NF-κB-dependent and -independent epigenetic modulation using the novel anti-cancer agent DMAPT.
Nakshatri H; Appaiah HN; Anjanappa M; Gilley D; Tanaka H; Badve S; Crooks PA; Mathews W; Sweeney C; Bhat-Nakshatri P
Cell Death Dis; 2015 Jan; 6(1):e1608. PubMed ID: 25611383
[TBL] [Abstract] [Full Text] [Related]
14. Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen.
Mendes-Pereira AM; Sims D; Dexter T; Fenwick K; Assiotis I; Kozarewa I; Mitsopoulos C; Hakas J; Zvelebil M; Lord CJ; Ashworth A
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2730-5. PubMed ID: 21482774
[TBL] [Abstract] [Full Text] [Related]
15. ERK activation and cell growth require CaM kinases in MCF-7 breast cancer cells.
Schmitt JM; Abell E; Wagner A; Davare MA
Mol Cell Biochem; 2010 Feb; 335(1-2):155-71. PubMed ID: 19763792
[TBL] [Abstract] [Full Text] [Related]
